logo
Wells Fargo Keeps Their Buy Rating on TransUnion (TRU)

Wells Fargo Keeps Their Buy Rating on TransUnion (TRU)

Wells Fargo analyst Jason Haas CFA maintained a Buy rating on TransUnion yesterday and set a price target of $118.00. The company's shares closed yesterday at $99.22.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Haas CFA is ranked #749 out of 9862 analysts.
In addition to Wells Fargo, TransUnion also received a Buy from BMO Capital's Ryan Griffin CFA in a report issued yesterday. However, on the same day, Goldman Sachs maintained a Hold rating on TransUnion (NYSE: TRU).
Based on TransUnion's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.14 billion and a net profit of $287.8 million. In comparison, last year the company earned a revenue of $1.04 billion and had a net profit of $85 million
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Yahoo

time14 minutes ago

  • Yahoo

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

UBS Keeps Their Buy Rating on Ampol Limited (CTXAF)
UBS Keeps Their Buy Rating on Ampol Limited (CTXAF)

Business Insider

time28 minutes ago

  • Business Insider

UBS Keeps Their Buy Rating on Ampol Limited (CTXAF)

UBS analyst Tom Allen maintained a Buy rating on Ampol Limited today and set a price target of A$31.50. The company's shares closed last Friday at $16.30. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Allen covers the Energy sector, focusing on stocks such as Santos Limited, Origin Energy Limited, and Beach Energy . According to TipRanks, Allen has an average return of 9.1% and a 61.84% success rate on recommended stocks. In addition to UBS, Ampol Limited also received a Buy from Morgan Stanley's Robert Koh in a report issued on July 24. However, on the same day, J.P. Morgan maintained a Hold rating on Ampol Limited (Other OTC: CTXAF). The company has a one-year high of $24.02 and a one-year low of $14.43. Currently, Ampol Limited has an average volume of 750.

Canaccord Genuity Keeps Their Buy Rating on Paladin Energy Ltd (PALAF)
Canaccord Genuity Keeps Their Buy Rating on Paladin Energy Ltd (PALAF)

Business Insider

time28 minutes ago

  • Business Insider

Canaccord Genuity Keeps Their Buy Rating on Paladin Energy Ltd (PALAF)

Canaccord Genuity analyst James Bullen maintained a Buy rating on Paladin Energy Ltd on July 24 and set a price target of A$12.60. The company's shares closed last Friday at $4.72. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bullen covers the Energy sector, focusing on stocks such as Amplitude Energy, Paladin Energy Ltd, and Bannerman Energy. According to TipRanks, Bullen has an average return of 2.1% and a 45.99% success rate on recommended stocks. In addition to Canaccord Genuity, Paladin Energy Ltd also received a Buy from Morgan Stanley's Shannon Sinha in a report issued on July 24. However, on the same day, J.P. Morgan upgraded Paladin Energy Ltd (Other OTC: PALAF) to a Hold. PALAF market cap is currently $1.92B and has a P/E ratio of -125.87.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store